Diligence memo · auto-generated · as of July 2, 2026
TwinStrand Biosciences, Inc.
TwinStrand Biosciences, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
TwinStrand Biosciences, Inc. operates in Biotech / Pharma, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
TwinStrand Biosciences, Inc. has raised $85M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $50M on 2021-04-30.
Most recent recorded round closed around 2023-06-20.
Valuation (modeled)modeled
Provath models TwinStrand Biosciences, Inc. at approximately $132M (range $33M–$232M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.26× the median modeled value of Series C Biotech / Pharma companies in 2022–2024 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 3.0 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 4.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: Sherlock Biosciences, Inc., Pacific Biosciences Of California, Inc., Sudo Biosciences, Inc., Elephas Biosciences Corp, NOLA PharmaHoldings, LLC.
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.